Izrael - angleščina - Ministry of Health

bristol - myers squibb, israel - entecavir; entecavir - film coated tablets - entecavir 0.5 mg; entecavir 0.5 mg - entecavir - entecavir - baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with: - compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. - decompensated liver disease. baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with: - compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. - decompensated liver disease.

Evropska unija - angleščina - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - entecavir - hepatitis b, chronic - antivirals for systemic use - baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with:compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis;decompensated liver disease.for both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with hbeag positive and hbeag negative hbv infection. with respect to patients with lamivudine-refractory hepatitis b.

Irska - angleščina - HPRA (Health Products Regulatory Authority)

actavis uk limited - entecavir monohydrate - film coated tablet - 0.5 milligram - nucleoside and nucleotide reverse transcriptase inhibitors

Irska - angleščina - HPRA (Health Products Regulatory Authority)

actavis uk limited - entecavir monohydrate - film coated tablet - 1 milligram - nucleoside and nucleotide reverse transcriptase inhibitors

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - entecavir monohydrate - tablet - 500microgram

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol-myers squibb pharmaceuticals ltd - entecavir monohydrate - tablet - 1mg

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

dr reddy's laboratories (uk - entecavir monohydrate - tablet - 500microgram

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

dr reddy's laboratories (uk - entecavir monohydrate - tablet - 1mg

Evropska unija - angleščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - entecavir - hepatitis b, chronic - antivirals for systemic use - entecavir accord is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with: , compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis., decompensated liver disease. , for both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with hbeag positive and hbeag negative hbv infection. with respect to patients with lamivudine-refractory hepatitis b. entecavir accord is also indicated for the treatment of chronic hbv infection in nucleoside naive paediatric patients from 2 to

Malta - angleščina - Medicines Authority

pharos – pharmaceutical oriented services limited lesvou str. (end), thesi loggos, industrial zone, 144 52 metamorfossi attikis,, greece - entecavir hydrate - film-coated tablet - entecavir hydrate 0.5 mg - antivirals for systemic use